Loading...
•
Dec 31, 2024
Pfizer Q4 2024 Earnings Report
Key Takeaways
Pfizer delivered strong Q4 2024 results, reporting $17.8 billion in revenue, a 21% year-over-year operational increase. Adjusted EPS was $0.63, up from $0.10 in Q4 2023. Growth was driven by increased sales in oncology, Eliquis, and the Vyndaqel family, though partially offset by a decline in Comirnaty revenue.
Pfizer
Pfizer
Pfizer Revenue by Segment
Revenue by Segment
Biopharma Revenue
CapyFin.comPfizer CentreOne Revenue
CapyFin.comPfizer Ignite Revenue
CapyFin.com Forward Guidance
Pfizer reaffirms its 2025 guidance, expecting revenue between $61-64 billion and adjusted EPS of $2.80-$3.00, with continued cost-saving measures and product growth outside COVID-related sales.
Positive Outlook
- Expected 2025 revenue in the $61-64 billion range.
- Projected adjusted EPS between $2.80 and $3.00.
- Continued cost realignment program targeting $4.5 billion in savings.
- Growth expected from non-COVID products including oncology and Eliquis.
- Manufacturing optimization program on track for cost savings.
Challenges Ahead
- Declining COVID-related revenue expected to impact total revenue.
- Some products facing generic competition leading to revenue declines.
- Supply constraints affecting oncology biosimilars.
- Declining demand for Abrysvo due to reduced vaccination rates.
- Lower Xeljanz sales due to market shifts and pricing pressure.
Revenue & Expenses
Visualization of income flow from segment revenue to net income